A detailed history of Israel Englander (Millennium Management LLC) transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,237,572 shares of CMPX stock, worth $15.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,237,572
Previous 851,205 280.35%
Holding current value
$15.8 Million
Previous $2.21 Million 448.58%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$2.52 - $3.82 $6.01 Million - $9.12 Million
2,386,367 Added 280.35%
3,237,572 $12.1 Million
Q2 2025

Aug 14, 2025

BUY
$1.46 - $2.69 $446,930 - $823,454
306,117 Added 56.16%
851,205 $2.21 Million
Q1 2025

May 15, 2025

BUY
$1.4 - $3.9 $715,723 - $1.99 Million
511,231 Added 1509.97%
545,088 $1.04 Million
Q4 2024

Feb 14, 2025

SELL
$1.35 - $1.98 $182,987 - $268,381
-135,546 Reduced 80.01%
33,857 $49,000
Q3 2024

Nov 14, 2024

SELL
$0.8 - $1.88 $211,481 - $496,981
-264,352 Reduced 60.95%
169,403 $311,000
Q2 2024

Aug 14, 2024

BUY
$1.0 - $1.85 $239,988 - $443,977
239,988 Added 123.85%
433,755 $433,000
Q1 2024

May 15, 2024

SELL
$1.2 - $2.29 $360,390 - $687,744
-300,325 Reduced 60.78%
193,767 $383,000
Q4 2023

Feb 14, 2024

BUY
$1.4 - $1.98 $462,876 - $654,639
330,626 Added 202.26%
494,092 $770,000
Q2 2023

Aug 14, 2023

SELL
$2.64 - $3.48 $2.15 Million - $2.84 Million
-814,937 Reduced 83.29%
163,466 $519,000
Q1 2023

May 15, 2023

BUY
$3.14 - $5.48 $2.81 Million - $4.91 Million
896,456 Added 1093.95%
978,403 $3.2 Million
Q4 2022

Feb 14, 2023

BUY
$2.55 - $5.41 $47,838 - $101,491
18,760 Added 29.69%
81,947 $412,000
Q3 2022

Nov 14, 2022

BUY
$1.9 - $3.37 $67,119 - $119,048
35,326 Added 126.79%
63,187 $144,000

Others Institutions Holding CMPX

About Compass Therapeutics, Inc.


  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $494M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.